Lymphodepletional strategies in transplantation.
暂无分享,去创建一个
S. Knechtle | J. Kwun | B. Oh | E. Page
[1] W. Chapman,et al. Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] S. Knechtle,et al. Patterns of De Novo Allo B Cells and Antibody Formation in Chronic Cardiac Allograft Rejection After Alemtuzumab Treatment , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] G. Lal,et al. NK Cells are Required for Costimulatory Blockade Induced Tolerance to Vascularized Allografts , 2012, Transplantation.
[4] S. Knechtle,et al. Enhanced De Novo Alloantibody and Antibody‐Mediated Injury in Rhesus Macaques , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] M. Ruzek,et al. Transient Low-Dose Methotrexate Induces Tolerance to Murine Anti-Thymocyte Globulin and Together They Promote Long-Term Allograft Survival , 2012, The Journal of Immunology.
[6] A. Kirk,et al. Alternative Immunomodulatory Strategies for Xenotransplantation: CD40/154 Pathway‐Sparing Regimens Promote Xenograft Survival , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] D. Scott,et al. Endogenous Expansion of Regulatory T Cells Leads to Long‐Term Islet Graft Survival in Diabetic NOD Mice , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] S. Knechtle,et al. The role of B cells in solid organ transplantation. , 2012, Seminars in immunology.
[9] S. Strober,et al. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. , 2012, Blood.
[10] R. Colvin,et al. A Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and Alloantibody , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] D. Sachs,et al. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin. , 2011, Bioconjugate chemistry.
[12] R. Redfield,et al. Essential role for B cells in transplantation tolerance. , 2011, Current opinion in immunology.
[13] D. Sachs,et al. First Experience With the Use of a Recombinant CD3 Immunotoxin as Induction Therapy in Pig-to-Primate Xenotransplantation: The Effect of T-Cell Depletion on Outcome , 2011, Transplantation.
[14] S. Mulgaonkar,et al. Alemtuzumab induction in renal transplantation. , 2011, The New England journal of medicine.
[15] P. Friend,et al. Th17 Cells in Alemtuzumab-Treated Patients: The Effect of Long-Term Maintenance Immunosuppressive Therapy , 2011, Transplantation.
[16] S. Crotty,et al. Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.
[17] A. Monaco,et al. 25 Years and New Frontiers in Solid Organ Transplantation and Haematology , 2011 .
[18] T. Coffman,et al. B Lymphocytes Differentially Influence Acute and Chronic Allograft Rejection in Mice , 2011, The Journal of Immunology.
[19] S. Soker,et al. Clinical Operational Tolerance After Renal Transplantation: Current Status and Future Challenges , 2010, Annals of surgery.
[20] J. Brenchley,et al. Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates. , 2010, Blood.
[21] C. Klein,et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.
[22] E. Morelon,et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. , 2010, Transplant immunology.
[23] R. Pierson,et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. , 2010, The Journal of clinical investigation.
[24] J. Ijzermans,et al. Investigation of Lymphocyte Depletion and Repopulation Using Alemtuzumab (Campath‐1H) in Cynomolgus Monkeys , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] J. Dumortier,et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: A five‐year randomized prospective study , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[26] J. Fechner,et al. BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] M. Ban,et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). , 2009, The Journal of clinical investigation.
[28] Kenneth G. C. Smith,et al. B-cell-depleting induction therapy and acute cellular rejection. , 2009, The New England journal of medicine.
[29] D. San Segundo,et al. Changes in the serum levels of interleukin‐17/interleukin‐23 during acute rejection in liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[30] J. Desjarlais,et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. , 2009, Blood.
[31] G. Verleden,et al. The Role of the IL23/IL17 Axis in Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[32] C. Hunter,et al. With a little help from their friends: interleukin-21, T cells, and B cells. , 2008, Immunity.
[33] C. Drachenberg,et al. Thymoglobulin Dose Optimization for Induction Therapy in High Risk Kidney Transplant Recipients , 2008, Transplantation.
[34] Eric Vivier,et al. Functions of natural killer cells , 2008, Nature Immunology.
[35] T. Starzl,et al. Alemtuzumab Preconditioning With Tacrolimus Monotherapy—The Impact of Serial Monitoring for Donor-Specific Antibody , 2008, Transplantation.
[36] Yong Zhao,et al. Depleting Anti-CD4 Monoclonal Antibody (GK1.5) Treatment: Influence on Regulatory CD4+CD25+Foxp3+ T Cells in Mice , 2008, Transplantation.
[37] J. Fechner,et al. CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath‐1H , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[38] A. Monaco,et al. SV40 Infection Associated With Rituximab Treatment After Kidney Transplantation in Nonhuman Primates , 2008, Transplantation.
[39] Thomas F. Tedder,et al. Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1 , 2008, The Journal of Immunology.
[40] A. Vats,et al. Alemtuzumab Pre‐Conditioning With Tacrolimus Monotherapy in Pediatric Renal Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[41] P. Munson,et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. , 2007, Blood.
[42] M. Rickels,et al. B lymphocyte–directed immunotherapy promotes long-term islet allograft survival in nonhuman primates , 2007, Nature Medicine.
[43] A. Kirk,et al. Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] D. Neville,et al. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. , 2007, Protein engineering, design & selection : PEDS.
[45] M. Mohty,et al. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.
[46] A. Kirk,et al. CD154 Blockade, Sirolimus, and Donor-Specific Transfusion Prevents Renal Allograft Rejection in Cynomolgus Monkeys Despite Homeostatic T-Cell Activation , 2007, Transplantation.
[47] R. Colvin,et al. Depletion of CD8 Memory T Cells for Induction of Tolerance of a Previously Transplanted Kidney Allograft , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[48] D. Danilenko,et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. , 2007, Blood.
[49] K. Hardinger,et al. Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation , 2006, Pharmacotherapy.
[50] D. Brennan,et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.
[51] P. Friend,et al. Recipient Memory-Like Lymphocytes Remain Unresponsive to Graft Antigens After CAMPATH-1H Induction with Reduced Maintenance Immunosuppression , 2006, Transplantation.
[52] S. Knechtle,et al. The evolving role of alemtuzumab (Campath‐1H) for immunosuppressive therapy in organ transplantation , 2006, Transplant international : official journal of the European Society for Organ Transplantation.
[53] A. Webster,et al. Monoclonal and Polyclonal Antibody Therapy for Treating Acute Rejection in Kidney Transplant Recipients: A Systematic Review of Randomized Trial Data , 2006, Transplantation.
[54] J. Markmann,et al. Accelerated Memory Cell Homeostasis during T Cell Depletion and Approaches to Overcome It , 2006, The Journal of Immunology.
[55] Shaoming Huang,et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation , 2006, Transplant International.
[56] U. Christians,et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates , 2006, Nature Medicine.
[57] M. Carrier,et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy , 2005, Transplant international : official journal of the European Society for Organ Transplantation.
[58] Keiji Oi,et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. , 2005, The Journal of thoracic and cardiovascular surgery.
[59] J. Gaynor,et al. A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1 , 2005, Transplantation.
[60] Kenneth G. C. Smith,et al. Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[61] A. Kirk,et al. Immunocompetent T‐Cells with a Memory‐Like Phenotype are the Dominant Cell Type Following Antibody‐Mediated T‐Cell Depletion , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[62] D. Dunn,et al. Fungal infections in transplant recipients receiving alemtuzumab. , 2005, Transplantation proceedings.
[63] T. Starzl,et al. Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus , 2004, Transplantation.
[64] R. Colvin,et al. CD154 Blockade for Induction of Mixed Chimerism and Prolonged Renal Allograft Survival in Nonhuman Primates , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[65] R. Bontrop,et al. Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF-β1+CD4+ T Regulatory Cell Infiltrates1 , 2004, The Journal of Immunology.
[66] C. Ricordi,et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY7201 , 2004, Transplantation.
[67] G. Jhangri,et al. Herpes Zoster Infection Following Solid Organ Transplantation: Incidence, Risk Factors and Outcomes in the Current Immunosuppressive Era , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[68] L. Swinnen,et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 , 2003, Transplantation.
[69] J. Fechner,et al. Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection1 , 2003, Transplantation.
[70] D. Harlan,et al. RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52‐SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH‐1H) , 2003, Transplantation.
[71] D. Harlan,et al. RABBIT ANTITHYMOCYTE GLOBULIN INDUCTION AND SIROLIMUS MONOTHERAPY SUPPORTS PROLONGED ISLET ALLOGRAFT FUNCTION IN A NONHUMAN PRIMATE ISLET TRANSPLANTATION MODEL , 2003, Transplantation.
[72] Paulo Fontes,et al. Tolerogenic immunosuppression for organ transplantation , 2003, The Lancet.
[73] G. Szot,et al. CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo1 , 2003, The Journal of Immunology.
[74] D. Harlan,et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy , 2002, The Lancet.
[75] V. Brinkmann,et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD , 2002, Transplantation.
[76] A. Aruffo,et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques1 , 2002, Transplantation.
[77] Stephen C. Jameson,et al. Maintaining the norm: T-cell homeostasis , 2002, Nature Reviews Immunology.
[78] R. Poropatich,et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. , 2002, Annals of epidemiology.
[79] H. Meier‐Kriesche,et al. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. , 2002, Journal of the American Society of Nephrology : JASN.
[80] T. Batiuk,et al. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers , 2002, Clinical transplantation.
[81] M. Carson,et al. A Ligand for the Chemokine Receptor CCR7 Can Influence the Homeostatic Proliferation of CD4 T Cells and Progression of Autoimmunity1 , 2001, The Journal of Immunology.
[82] R. Buelow,et al. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. , 2001, Transplant immunology.
[83] Yulian Wu,et al. A proteasome inhibitor effectively prevents mouse heart allograft rejection. , 2001, Transplantation.
[84] S. Knechtle. Treatment with immunotoxin. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[85] G. Hale,et al. The CD52 antigen and development of the CAMPATH antibodies. , 2001, Cytotherapy.
[86] J. Revillard,et al. MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1 , 2001, Transplantation.
[87] H. Schuurman,et al. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD. , 2000, Transplant immunology.
[88] J. Bradley,et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. , 1999, Transplantation.
[89] H. Schuurman,et al. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons. , 1999, Transplant immunology.
[90] C. Janeway,et al. Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. , 1999, Immunity.
[91] J. Wain,et al. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. , 1999, Transplantation.
[92] N. Armstrong,et al. Primate renal transplants using immunotoxin. , 1998, Surgery.
[93] P. Friend,et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients , 1998, The Lancet.
[94] B. Sido,et al. Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production , 1998, European journal of immunology.
[95] M. Béné,et al. Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[96] D. Neville,et al. Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin. , 1997, Bioconjugate chemistry.
[97] R. Buelow,et al. Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. , 1997, Transplant immunology.
[98] J. Fechner,et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. , 1997, Transplantation.
[99] C. Orosz,et al. Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody. , 1996, Transplantation.
[100] C. Marboe,et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. , 1996, Transplantation.
[101] G. Opelz. EFFICACY OF REJECTION PROPHYLAXIS WITH OKT3 IN RENAL TRANSPLANTATION , 1995, Transplantation.
[102] D. M. Hamlin,et al. COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI‐CD ANTIGEN ANALYSIS BY FLOW CYTOMETRY , 1995, Transplantation.
[103] J. Kupiec-Weglinski,et al. alpha/beta-T cell receptor-directed therapy in rat cardiac allograft recipients. Treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection. , 1995, Transplantation.
[104] R. Colvin,et al. Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus Monkeys , 1995, Transplantation.
[105] J. Thomas,et al. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. , 1994, Transplantation.
[106] K. Wood,et al. Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti‐CD4 monoclonal antibody , 1993, Clinical and experimental immunology.
[107] F. Delmonico,et al. Nonhuman primate responses to murine and humanized OKT4A. , 1993, Transplantation.
[108] G. Aversa,et al. INDUCTION OF LONG‐TERM SPECIFIC TOLERANCE TO ALLOGRAFTS IN RATS BY THERAPY WITH AN ANTI‐CD3-LIKE MONOCLONAL ANTIBODY , 1993, Transplantation.
[109] J. Bluestone,et al. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. , 1992, Journal of Immunology.
[110] D. Neville,et al. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[111] R. Schooley,et al. SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2 , 1992, Transplantation.
[112] S. Rudnick,et al. OKT3E, AN ANTI‐CD3 ANTIBODY THAT DOES NOT ELICIT SIDE EFFECTS OR ANTIIDIOTYPE RESPONSES IN CHIMPANZEES , 1991, Transplantation.
[113] J. Gartner,et al. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. , 1991, The Journal of pediatrics.
[114] C. Vincent,et al. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. , 1991, Transplantation.
[115] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.
[116] I. Penn. Cancers complicating organ transplantation. , 1990, The New England journal of medicine.
[117] R. Colvin,et al. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. , 1990, Surgery.
[118] C. Ferran,et al. IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.
[119] K. Leunissen,et al. EVIDENCE OF INVOLVEMENT OF TUMOR NECROSIS FACTOR IN ADVERSE REACTIONS DURING TREATMENT OF KIDNEY ALLOGRAFT REJECTION WITH ANTITHYMOCYTE GLOBULIN , 1989, Transplantation.
[120] F. Thomas,et al. PROMOTION OF INCOMPATIBLE ALLOGRAFT ACCEPTANCE IN RHESUS MONKEYS GIVEN POSTTRANSPLANT ANTITHYMOCYTE GLOBULIN AND DONOR BONE MARROW: II. EFFECTS OF ADJUVANT IMMUNOSUPPRESSIVE DRUGS' , 1989, Transplantation.
[121] E. Reinherz,et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. , 1985, Blood.
[122] G. Boulianne,et al. Production of functional chimaeric mouse/human antibody , 1984, Nature.
[123] S L Morrison,et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[124] J. Thomas,et al. Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. , 1983, Annals of surgery.
[125] G. Goldstein,et al. EFFECTS OF IN VIVO ADMINISTRATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN T CELL SUBPOPULATIONS ON THE IMMUNE SYSTEM IN A RHESUS MONKEY MODEL , 1983, Transplantation.
[126] E. Reinherz,et al. Monoclonal antibodies defining distinctive human T cell surface antigens. , 1979, Science.
[127] J. Najarian,et al. The clinical use of antilymphocyte globulin. , 1971, The New England journal of medicine.
[128] T. Starzl,et al. THE CLINICAL USE OF ANTILYMPHOCYTE GLOBULIN IN RENAL HOMOTRANSPLANTATION , 1967, Transplantation.
[129] T. Starzl,et al. THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. , 1963, Surgery, gynecology & obstetrics.
[130] Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. , 2012, The Journal of pathology.
[131] Joan W. Miller,et al. Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .
[132] J. Markmann,et al. Homeostatic proliferation is a barrier to transplantation tolerance , 2004, Nature Medicine.
[133] D. Melvin,et al. Antimurine antibody formation following OKT3 therapy. , 1990, Transplantation.